Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3871801 Tablet vs Suspension in Healthy Participants
NCT05222399Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ocadusertib in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration Versus Time Curve. Started Feb 2022; status: completed.
02
Drugs
ocadusertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05222399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222399.